Search

Your search keyword '"Slavin, Monica A"' showing total 1,353 results
Start Over Author "Slavin, Monica A"
1,353 results on '"Slavin, Monica A"'

1. Oral challenge vs routine care to assess low-risk penicillin allergy in critically ill hospital patients (ORACLE): a pilot safety and feasibility randomised controlled trial

Author

Rose, Morgan T., Holmes, Natasha E., Eastwood, Glenn M., Vogrin, Sara, James, Fiona, De Luca, Joseph F., Bellomo, Rinaldo, Warrillow, Stephen J., Phung, Michelle, Barnes, Sara L., Murfin, Brendan, Rogers, Ben, Lambros, Belinda, Collis, Brennan, Peel, Trisha N., Slavin, Monica A., and Trubiano, Jason A.

Published
2024
Full Text
View/download PDF

3. Antibody titres elicited by the 2018 seasonal inactivated influenza vaccine decline by 3 months post-vaccination but persist for at least 6 months.

Author

Mordant, Francesca, Price, Olivia, Rudraraju, Rajeev, Slavin, Monica, Marshall, Caroline, Worth, Leon, Peck, Heidi, Barr, Ian, Sullivan, Sheena, and Subbarao, Kanta

Subjects
antibody, influenza, kinetics, serosurvey, vaccine, Humans, Aged, Influenza, Human, Influenza Vaccines, Seasons, Vaccines, Inactivated, Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype, Prospective Studies, Antibodies, Viral, Vaccination, Hemagglutination Inhibition Tests
Abstract

BACKGROUND: In Australia, seasonal inactivated influenza vaccine is typically offered in April. However, the onset, peak and end of a typical influenza season vary, and optimal timing for vaccination remains unclear. Here, we investigated vaccine-induced antibody response kinetics over 6 months in different age groups. METHODS: We conducted a prospective serosurvey among 71 adults aged 18-50 years, 15 community-dwelling (healthy) and 16 aged-care facility resident (frail) older adults aged ≥65 years who received the 2018 southern hemisphere vaccines. Sera were collected at baseline, and 1, 2, 4, and 6 months post-vaccination. Antibody titres were measured by haemagglutination inhibition or microneutralisation assays. Geometric mean titres were estimated using random effects regression modelling and superimposed on 2014-2018 influenza season epidemic curves. RESULTS: Antibody titres peaked 1.2-1.3 months post-vaccination for all viruses, declined by 3 months post-vaccination but, notably, persisted above baseline after 6 months in all age groups by 1.3- to 1.5-fold against A(H1N1)pdm09, 1.7- to 2-fold against A(H3N2), 1.7- to 2.1-fold against B/Yamagata and 1.8-fold against B/Victoria. Antibody kinetics were similar among different age groups. Antibody responses were poor against cell-culture grown compared to egg-grown viruses. CONCLUSIONS: These results suggest subtype-specific antibody-mediated protection persists for at least 6 months, which corresponds to the duration of a typical influenza season.

Published
2023

10. Guidelines for the management of Toxoplasma gondii infection and disease in patients with haematological malignancies and after haematopoietic stem-cell transplantation: guidelines from the 9th European Conference on Infections in Leukaemia, 2022

Author

Aerts, Robina, Mehra, Varun, Groll, Andreas H, Martino, Rodrigo, Lagrou, Katrien, Robin, Christine, Perruccio, Katia, Blijlevens, Nicole, Nucci, Marcio, Slavin, Monica, Bretagne, Stéphane, and Cordonnier, Catherine

Published
2024
Full Text
View/download PDF

11. When to change treatment of acute invasive aspergillosis: an expert viewpoint

Author

Slavin, Monica A, Chen, Yee-Chun, Cordonnier, Catherine, Cornely, Oliver A, Cuenca-Estrella, Manuel, Donnelly, J Peter, Groll, Andreas H, Lortholary, Olivier, Marty, Francisco M, Nucci, Marcio, Rex, John H, Rijnders, Bart JA, Thompson, George R, Verweij, Paul E, White, P Lewis, Hargreaves, Ruth, Harvey, Emma, and Maertens, Johan A

Subjects
Infectious Diseases, Clinical Trials and Supportive Activities, Rare Diseases, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Infection, Antifungal Agents, Aspergillosis, Bronchoalveolar Lavage Fluid, Humans, Immunocompromised Host, Invasive Fungal Infections, Invasive Pulmonary Aspergillosis, Mannans, Microbiology, Medical Microbiology, Pharmacology and Pharmaceutical Sciences
Abstract

Invasive aspergillosis (IA) is an acute infection affecting patients who are immunocompromised, as a result of receiving chemotherapy for malignancy, or immunosuppressant agents for transplantation or autoimmune disease. Whilst criteria exist to define the probability of infection for clinical trials, there is little evidence in the literature or clinical guidelines on when to change antifungal treatment in patients who are receiving prophylaxis or treatment for IA. To try and address this significant gap, an advisory board of experts was convened to develop criteria for the management of IA for use in designing clinical trials, which could also be used in clinical practice. For primary treatment failure, a change in antifungal therapy should be made: (i) when mycological susceptibility testing identifies an organism from a confirmed site of infection, which is resistant to the antifungal given for primary therapy, or a resistance mutation is identified by molecular testing; (ii) at, or after, 8 days of primary antifungal treatment if there is increasing serum galactomannan, or galactomannan positivity in serum, or bronchoalveolar lavage fluid when the antigen was previously undetectable, or there is sudden clinical deterioration, or a new clearly distinct site of infection is detected; and (iii) at, or after, 15 days of primary antifungal treatment if the patient is clinically stable but with ≥2 serum galactomannan measurements persistently elevated compared with baseline or increasing, or if the original lesions on CT or other imaging, show progression by >25% in size in the context of no apparent change in immune status.

Published
2021

13. Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients

Author

Teh, Benjamin W, Mikulska, Malgorzata, Averbuch, Dina, de la Camara, Rafael, Hirsch, Hans H, Akova, Murat, Ostrosky-Zeichner, Luis, Baddley, John W, Tan, Ban Hock, Mularoni, Alessandra, Subramanian, Aruna K, La Hoz, Ricardo M, Marinelli, Tina, Boan, Peter, Aguado, Jose Maria, Grossi, Paolo A, Maertens, Johan, Mueller, Nicolas J, and Slavin, Monica A

Published
2024
Full Text
View/download PDF

15. Invasive aspergillosis in adult patients in Australia and New Zealand: 2017–2020

Author

Tio, Shio Yen, Chen, Sharon C.-A., Hamilton, Kate, Heath, Christopher H., Pradhan, Alyssa, Morris, Arthur J., Korman, Tony M., Morrissey, Orla, Halliday, Catriona L., Kidd, Sarah, Spelman, Timothy, Brell, Nadiya, McMullan, Brendan, Clark, Julia E., Mitsakos, Katerina, Hardiman, Robyn P., Williams, Phoebe, Campbell, Anita J., Beardsley, Justin, Van Hal, Sebastiaan, Yong, Michelle K., Worth, Leon J., and Slavin, Monica A.

Published
2023
Full Text
View/download PDF

17. COVID-19 infection among patients with cancer in Australia from 2020 to 2022: a national multicentre cohort study

Author

Hall, Victoria G., Sim, Beatrice Z., Lim, Chhay, Hocking, Christopher, Teo, Teddy, Runnegar, Naomi, Boan, Peter, Heath, Christopher H., Rainey, Natalie, Lyle, Megan, Steer, Christopher, Liu, Eunice, Doig, Cassandra, Drummond, Kate, Charles, Patrick G.P., See, Katharine, Lim, Lyn-Li, Shum, Omar, Bak, Narin, Mclachlan, Sue-Anne, Singh, Kasha P., Laundy, Nicholas, Gallagher, Jenny, Stewart, Marcelle, Saunders, Natalie R., Klimevski, Emily, Demajo, Jessica, Reynolds, Gemma, Thursky, Karin A., Worth, Leon J., Spelman, Timothy, Yong, Michelle K., Slavin, Monica A., and Teh, Benjamin W.

Published
2023
Full Text
View/download PDF

19. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium

Author

Donnelly, J Peter, Chen, Sharon C, Kauffman, Carol A, Steinbach, William J, Baddley, John W, Verweij, Paul E, Clancy, Cornelius J, Wingard, John R, Lockhart, Shawn R, Groll, Andreas H, Sorrell, Tania C, Bassetti, Matteo, Akan, Hamdi, Alexander, Barbara D, Andes, David, Azoulay, Elie, Bialek, Ralf, Bradsher, Robert W, Bretagne, Stephane, Calandra, Thierry, Caliendo, Angela M, Castagnola, Elio, Cruciani, Mario, Cuenca-Estrella, Manuel, Decker, Catherine F, Desai, Sujal R, Fisher, Brian, Harrison, Thomas, Heussel, Claus Peter, Jensen, Henrik E, Kibbler, Christopher C, Kontoyiannis, Dimitrios P, Kullberg, Bart-Jan, Lagrou, Katrien, Lamoth, Frédéric, Lehrnbecher, Thomas, Loeffler, Jurgen, Lortholary, Olivier, Maertens, Johan, Marchetti, Oscar, Marr, Kieren A, Masur, Henry, Meis, Jacques F, Morrisey, C Orla, Nucci, Marcio, Ostrosky-Zeichner, Luis, Pagano, Livio, Patterson, Thomas F, Perfect, John R, Racil, Zdenek, Roilides, Emmanuel, Ruhnke, Marcus, Prokop, Cornelia Schaefer, Shoham, Shmuel, Slavin, Monica A, Stevens, David A, Thompson, George R, Vazquez, Jose A, Viscoli, Claudio, Walsh, Thomas J, Warris, Adilia, Wheat, L Joseph, White, P Lewis, Zaoutis, Theoklis E, and Pappas, Peter G

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Cancer, Prevention, Clinical Research, Good Health and Well Being, Antifungal Agents, Consensus, Humans, Immunocompromised Host, Invasive Fungal Infections, Mycoses, Neoplasms, consensus, definitions, invasive fungal diseases, diagnosis, research, Biological Sciences, Medical and Health Sciences, Microbiology, Clinical sciences
Abstract

BackgroundInvasive fungal diseases (IFDs) remain important causes of morbidity and mortality. The consensus definitions of the Infectious Diseases Group of the European Organization for Research and Treatment of Cancer and the Mycoses Study Group have been of immense value to researchers who conduct clinical trials of antifungals, assess diagnostic tests, and undertake epidemiologic studies. However, their utility has not extended beyond patients with cancer or recipients of stem cell or solid organ transplants. With newer diagnostic techniques available, it was clear that an update of these definitions was essential.MethodsTo achieve this, 10 working groups looked closely at imaging, laboratory diagnosis, and special populations at risk of IFD. A final version of the manuscript was agreed upon after the groups' findings were presented at a scientific symposium and after a 3-month period for public comment. There were several rounds of discussion before a final version of the manuscript was approved.ResultsThere is no change in the classifications of "proven," "probable," and "possible" IFD, although the definition of "probable" has been expanded and the scope of the category "possible" has been diminished. The category of proven IFD can apply to any patient, regardless of whether the patient is immunocompromised. The probable and possible categories are proposed for immunocompromised patients only, except for endemic mycoses.ConclusionsThese updated definitions of IFDs should prove applicable in clinical, diagnostic, and epidemiologic research of a broader range of patients at high-risk.

Published
2020

20. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium

Author

Cornely, Oliver A, Alastruey-Izquierdo, Ana, Arenz, Dorothee, Chen, Sharon CA, Dannaoui, Eric, Hochhegger, Bruno, Hoenigl, Martin, Jensen, Henrik E, Lagrou, Katrien, Lewis, Russell E, Mellinghoff, Sibylle C, Mer, Mervyn, Pana, Zoi D, Seidel, Danila, Sheppard, Donald C, Wahba, Roger, Akova, Murat, Alanio, Alexandre, Al-Hatmi, Abdullah MS, Arikan-Akdagli, Sevtap, Badali, Hamid, Ben-Ami, Ronen, Bonifaz, Alexandro, Bretagne, Stéphane, Castagnola, Elio, Chayakulkeeree, Methee, Colombo, Arnaldo L, Corzo-León, Dora E, Drgona, Lubos, Groll, Andreas H, Guinea, Jesus, Heussel, Claus-Peter, Ibrahim, Ashraf S, Kanj, Souha S, Klimko, Nikolay, Lackner, Michaela, Lamoth, Frederic, Lanternier, Fanny, Lass-Floerl, Cornelia, Lee, Dong-Gun, Lehrnbecher, Thomas, Lmimouni, Badre E, Mares, Mihai, Maschmeyer, Georg, Meis, Jacques F, Meletiadis, Joseph, Morrissey, C Orla, Nucci, Marcio, Oladele, Rita, Pagano, Livio, Pasqualotto, Alessandro, Patel, Atul, Racil, Zdenek, Richardson, Malcolm, Roilides, Emmanuel, Ruhnke, Markus, Seyedmousavi, Seyedmojtaba, Sidharthan, Neeraj, Singh, Nina, Sinko, János, Skiada, Anna, Slavin, Monica, Soman, Rajeev, Spellberg, Brad, Steinbach, William, Tan, Ban Hock, Ullmann, Andrew J, Vehreschild, Jörg J, Vehreschild, Maria JGT, Walsh, Thomas J, White, P Lewis, Wiederhold, Nathan P, Zaoutis, Theoklis, Chakrabarti, Arunaloke, and Group, Mucormycosis ECMM MSG Global Guideline Writing

Subjects
Clinical Research, Good Health and Well Being, Disease Management, Humans, Mucormycosis, Mucormycosis ECMM MSG Global Guideline Writing Group, Clinical Sciences, Medical Microbiology, Public Health and Health Services, Microbiology
Abstract

Mucormycosis is a difficult to diagnose rare disease with high morbidity and mortality. Diagnosis is often delayed, and disease tends to progress rapidly. Urgent surgical and medical intervention is lifesaving. Guidance on the complex multidisciplinary management has potential to improve prognosis, but approaches differ between health-care settings. From January, 2018, authors from 33 countries in all United Nations regions analysed the published evidence on mucormycosis management and provided consensus recommendations addressing differences between the regions of the world as part of the "One World One Guideline" initiative of the European Confederation of Medical Mycology (ECMM). Diagnostic management does not differ greatly between world regions. Upon suspicion of mucormycosis appropriate imaging is strongly recommended to document extent of disease and is followed by strongly recommended surgical intervention. First-line treatment with high-dose liposomal amphotericin B is strongly recommended, while intravenous isavuconazole and intravenous or delayed release tablet posaconazole are recommended with moderate strength. Both triazoles are strongly recommended salvage treatments. Amphotericin B deoxycholate is recommended against, because of substantial toxicity, but may be the only option in resource limited settings. Management of mucormycosis depends on recognising disease patterns and on early diagnosis. Limited availability of contemporary treatments burdens patients in low and middle income settings. Areas of uncertainty were identified and future research directions specified.

Published
2019

21. Robust SARS-CoV-2 T cell responses with common TCRαβ motifs toward COVID-19 vaccines in patients with hematological malignancy impacting B cells

Author

Nguyen, Thi H.O., Rowntree, Louise C., Allen, Lilith F., Chua, Brendon Y., Kedzierski, Lukasz, Lim, Chhay, Lasica, Masa, Tennakoon, G. Surekha, Saunders, Natalie R., Crane, Megan, Chee, Lynette, Seymour, John F., Anderson, Mary Ann, Whitechurch, Ashley, Clemens, E. Bridie, Zhang, Wuji, Chang, So Young, Habel, Jennifer R., Jia, Xiaoxiao, McQuilten, Hayley A., Minervina, Anastasia A., Pogorelyy, Mikhail V., Chaurasia, Priyanka, Petersen, Jan, Menon, Tejas, Hensen, Luca, Neil, Jessica A., Mordant, Francesca L., Tan, Hyon-Xhi, Cabug, Aira F., Wheatley, Adam K., Kent, Stephen J., Subbarao, Kanta, Karapanagiotidis, Theo, Huang, Han, Vo, Lynn K., Cain, Natalie L., Nicholson, Suellen, Krammer, Florian, Gibney, Grace, James, Fiona, Trevillyan, Janine M., Trubiano, Jason A., Mitchell, Jeni, Christensen, Britt, Bond, Katherine A., Williamson, Deborah A., Rossjohn, Jamie, Crawford, Jeremy Chase, Thomas, Paul G., Thursky, Karin A., Slavin, Monica A., Tam, Constantine S., Teh, Benjamin W., and Kedzierska, Katherine

Published
2023
Full Text
View/download PDF

24. A protocol for an international, multicentre pharmacokinetic study for Screening Antifungal Exposure in Intensive Care Units: The SAFE-ICU study

Author

Roberts, Jason A., Sime, Fekade, Lipman, Jeffrey, Hernández-Mitre, Maria Patricia, Baptista, João Pedro, Brüggemann, Roger J., Darvall, Jai, De Waele, Jan J., Dimopoulos, George, Lefrant, Jean-Yves, Mat Nor, Mohd Basri, Rello, Jordi, Seoane, Leonardo, Slavin, Monica A., Valkonen, Miia, Venditti, Mario, Wong, Wai Tat, Zeitlinger, Markus, and Roger, Claire

Published
2023
Full Text
View/download PDF

27. Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial

Author

Akova, Murat, AlAgha, Rawan, Alangaden, George, Albrecht, Svenja J, Alexander, Barbara, Al-Obaidi, Mohanad, Ambasch, German, Armestar Rodriguez, Fernando, Azap, Alpay, Baffoe-Bonnie, Anthony, Belkhir, Leila, Ben-Ami, Ronen, Boutoille, David, Cascio, Antonio, Chai, Louis YA, Chaiwarith, Romanee, Chayakulkeeree, Methee, Chen, Sharon, Chen, Yee-Chun, Chen, Yen-Hsu, Choi, Jun Yong, Choi, Young Hwa, Chotiprasitsakul, Darunee, Chung, Jin Won, Danion, François, Denis, Blandine, Diaz Santos, Emilio, Dictar, Miguel O, Diltoer, Marc, Dupont, Herve, Feng, Sizhou, Ferre Colomer, Maria Angeles, Ferrer, Ricard, Forel, Jean-Marie Fernand Roger, Fortún-Abete, Jesús, Garcia-Diaz, Julia, Girardis, Massimo, He, Fang, Hites, Maya, Ho, Mao-Wang, Honore, Patrick, Horcajada Gallego, Juan Pablo, Huang, Haihui, Huang, Po-Yen, Huang, Yong, Hussein, Osamah, Intalapaporn, Poj, Jaruratanasirikul, Sutep, Jauregui-Peredo, Luis, Johnson, Misty, Jung, Dong Sik, Jutivorakool, Kamonwan, Kern, Winfried V, Kett, Daniel H, Khawcharoenporn, Thana, Kim, Young Keun, Koehler, Philipp, Kotanidou, Anastasia, Lachiewicz, Anne, Lin, Qinhan, Lopez Cortes, Luis Eduardo, Luo, Hong, Luzzati, Roberto, Maor, Yasmin, McCarty, Todd, Merelli, Maria, Merino Amador, Paloma, Midturi, John, Migliorino, Guglielmo Marco, Mira, Jean-Paul, Mootsikapun, Piroon, Morrissey, Orla, Munoz Garcia de Paredes, Patricia, Mussini, Cristina, Mylonakis, Eleftherios, Nseir, Saadalla, Nseir, William, Odabasi, Zekaver, Papastamopoulos, Vasileios, Paterson, David, Patterson, Thomas F, Peck, Kyong Ran, Peng, Zhiyong, Permpalung, Nitipong, Plantefeve, Gaetan J, Poromanski, Ivan G, Powell, Debra, Psichogiou, Mina, Puah, Ser Hon, Pullman, John, Rahav, Galia, Martinez, Antonio Ramos, Ramos Ramos, Juan Carlos, Raz-Pasteur, Ayelet, Restrepo Castro, Carlos A, Riera, Fernando, Roblot, France, Rodriguez Alvarez, Regino Jose, Rogers, Benjamin, Roilides, Emmanuel, Sanchez Vallejo, Gregorio, Sganga, Gabriele, Sipsas, Nikolaos, Slavin, Monica, Soriano, Alex, Spec, Andrej, Strahilevitz, Jacob, Tancheva, Dora M, Tao, Zhen, Teschner, Daniel, Thompson, George R, Van Wijngaerden, Eric, Vazquez, Jose, Vergidis, Paschalis, Viale, Pierluigi, Wang, Fu-Der, Wang, Shifu, Weber, Gabriel, Weng, Jianyu, Xu, Jinfu, Yao, Li, Yavuz, Serap, Yilmaz, Mesut, Young, Jo-Anne, Zarate, Abel H, Zeng, Jun, Zhang, Yong, Thompson, George R, III, Cornely, Oliver A, Kullberg, Bart Jan, Kollef, Marin, Honore, Patrick M, Bassetti, Matteo, Poromanski, Ivan, Dignani, Cecilia, Das, Anita F, Sandison, Taylor, and Pappas, Peter G

Published
2023
Full Text
View/download PDF

30. Mycobacterial infections in adults with haematological malignancies and haematopoietic stem cell transplants: guidelines from the 8th European Conference on Infections in Leukaemia

Author

Greinix, Hildegard, Maertens, Johan, De Greef, Julien, Slavin, Monica, Spriet, Isabel, Hubacek, Petr, Bergeron, Anne, Cordonnier, Catherine, Kanerva, Jukka, Herbrecht, Raoul, Herrmann, Jean-Louis, Lanternier, Fanny, Bondeelle, Louise, Robin, Christine, Einsele, Hermann, Lehrnbecher, Thomas, Groll, Andreas, Maschmeyer, Georg, Lange, Christoph, von Lilienfeld-Toal, Marie, Pana, Dorothea, Roilides, Emmanuel, Kassa, Csaba, Averbuch, Diana, Engelhard, Dan, Cesaro, Simone, Mikulska, Malgorzata, Pagano, Livio, Castagnola, Elio, Compagno, Francesca, Goletti, Delia, Mesini, Alessio, Donnelly, Peter J, Styczynski, Jan, Botelho de Sousa, Aida, Aljurf, Mahmoud, de la Camara, Rafael, Navarro, David, Rovira, Montserrat, Franquet, Tomas, Garcia-Vidal, Carol, Ljungman, Per, Paukssen, Karlis, Ammann, Roland, Lamoth, Frédéric, Hirsch, Hans, Ritz, Nicole, Akova, Murat, Ceesay, Mansour, Warris, Adilia, Chemaly, Roy, and Donnelly, J Peter

Published
2022
Full Text
View/download PDF

31. [18F]FDG-PET-CT compared with CT for persistent or recurrent neutropenic fever in high-risk patients (PIPPIN): a multicentre, open-label, phase 3, randomised, controlled trial

Author

Douglas, Abby, Thursky, Karin, Spelman, Timothy, Szer, Jeff, Bajel, Ashish, Harrison, Simon, Tio, Shio Yen, Bupha-Intr, Olivia, Tew, Michelle, Worth, Leon, Teh, Benjamin, Chee, Lynette, Ng, Ashley, Carney, Dennis, Khot, Amit, Haeusler, Gabrielle, Yong, Michelle, Trubiano, Jason, Chen, Sharon, Hicks, Rodney, Ritchie, David, and Slavin, Monica

Published
2022
Full Text
View/download PDF

32. Multi-site implementation of whole genome sequencing for hospital infection control: A prospective genomic epidemiological analysis

Author

Sherry, Norelle L., Gorrie, Claire L., Kwong, Jason C., Higgs, Charlie, Stuart, Rhonda L., Marshall, Caroline, Ballard, Susan A., Sait, Michelle, Korman, Tony M., Slavin, Monica A., Lee, Robyn S., Graham, Maryza, Leroi, Marcel, Worth, Leon J., Chan, Hiu Tat, Seemann, Torsten, Grayson, M. Lindsay, and Howden, Benjamin P.

Published
2022
Full Text
View/download PDF

34. Infections during novel myeloma therapies.

Author

Liu, Alice J., Slavin, Monica A., Harrison, Simon J., and Teh, Benjamin W.

Abstract

AbstractNew generation therapies such as bispecific antibodies (BsAb), chimeric antigen receptor T-cell therapy (CAR T) and antibody-drug conjugates (ADC) have revolutionized the treatment of relapsed/refractory multiple myeloma (RRMM). However, there is emerging evidence of increased infection risk associated with these treatments in clinical trials and observational settings. This infection risk may be mediated by on-target, off-tumor side effects such as cytokine release syndrome, hypogammaglobulinaemia and cytopenias, disease-related humoral impairment and the consequences of multiple previous lines of treatment. While bacterial and viral pathogens predominate, reactivation of latent infection and opportunistic infections also warrant attention. This review characterizes the epidemiology of infections associated with novel therapies for RRMM to guide prophylaxis and antimicrobial prescribing in this patient population and highlights future areas of focus to inform ongoing infection prevention strategies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

35. Minimizing risk while maximizing opportunity: The infectious disease organ offer process survey.

Author

Prakash, Katya, Saharia, Kapil K., Karaba, Andrew, Law, Nancy, Albarillo, Fritzie S., Zangeneh, Tirdad T., Grossi, Paolo, Miller, Rachel, Slavin, Monica, Shoham, Shmuel, Ison, Michael, La Hoz, Ricardo M., and Baddley, John W.

Subjects
ACINETOBACTER infections, COMMUNICABLE diseases, PHYSICIANS, TRANSPLANTATION of organs, tissues, etc., INTERNET forums
Abstract

Background: The purpose of this study was to understand how transplant infectious disease (TID) physicians assess a potential donor with known or suspected infection and describe posttransplant management. Methods: We designed a survey of 10 organ offer scenarios and asked questions pertaining to organ acceptability for transplantation and management posttransplant. The survey was distributed to TID clinicians via transplant society listservs and email. Responses were recorded in REDCap, and descriptive statistics were employed. Results: One hundred thirteen infectious disease physicians responded to the survey, of whom 85 completed all cases. Respondents were generally in agreement regarding organ acceptability, although some divergence was seen when evaluating lungs from donors with influenza, tuberculosis, or multidrug‐resistant Acinetobacter infection. Posttransplant management showed more variation. Areas of optimization were identified: (1) Further understanding of where risk‐mitigation strategies within the donor offer process may improve donor acceptability and therefore organ utilization; (2) importance of recipient considerations in assessing degree of infectious risk; and (3) gaps in evidenced‐based data regarding optimal posttransplant management of recipients. Conclusion: Evaluation of donor offers by TID clinicians is a complex process. Although the survey does not itself serve to make recommendations regarding best practices, it highlights areas where generation of data to inform acceptance and management practices may allow for improved organ utilization and recipient management. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. Preneutropenic Fever in Patients With Hematological Malignancies: A Novel Target for Antimicrobial Stewardship.

Author

Chiodo-Reidy, Jessica, Slavin, Monica A, Tio, Shio Yen, Ng, Gywneth, Bajel, Ashish, Thursky, Karin A, and Douglas, Abby P

Subjects
*BONE marrow transplantation, *ACUTE myeloid leukemia, *HEMATOLOGIC malignancies, *ANTIMICROBIAL stewardship, *NEUTROPENIA
Abstract

Background Many patients with hematological malignancy develop fever after chemotherapy/conditioning but before chemotherapy-induced neutropenia (preneutropenic fever [PNF]). The proportion of PNF with an infectious etiology is not well established. Methods We conducted a single-center, prospective observational substudy of PNF (neutrophils >0.5 cells/μL, ≥38.0°C) in adults receiving acute myeloid leukemia (AML) chemotherapy, or allogeneic hematopoietic cell transplant (allo-HCT) conditioning enrolled in a neutropenic fever randomized controlled trial between 1 January and 31 October 2018. Eligible patients had anticipated neutropenia ≥10 days and exclusions included concurrent infection and/or neutropenia prior to chemotherapy or conditioning. PNF rates and infections encountered were described. Associations between noninfectious etiologies and fever were explored. Antimicrobial therapy prescription across preneutropenic and neutropenic periods was examined. Results Of 62 consecutive patients included (43 allo-HCT, 19 AML), 27 had PNF (44%) and 5 (19%) had an infective cause. Among allo-HCT, PNF occurred in 14 of 17 (82%) who received thymoglobulin; only 1 of 14 (7%) had infection. During AML chemotherapy, 18 of 19 received cytarabine, of which 8 of 18 (44%) had PNF and 3 of 8 (38%) had infection. Most patients with PNF had antimicrobial therapy continued into the neutropenic period (19/27 [70%]). Those with PNF were more likely to be escalated to broader antimicrobial therapy at onset/during neutropenic fever (5/24 [21%] vs 2/30 [7%]). Conclusions Rates of PNF were high, and documented infection low, leading to prolonged and escalating antimicrobial therapy. In the absence of infection, early cessation of empiric therapy after PNF is recommended as an important stewardship intervention. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

50. Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology

Author

Hoenigl, Martin, Salmanton-García, Jon, Walsh, Thomas J, Nucci, Marcio, Neoh, Chin Fen, Jenks, Jeffrey D, Lackner, Michaela, Sprute, Rosanne, Al-Hatmi, Abdullah M S, Bassetti, Matteo, Carlesse, Fabianne, Freiberger, Tomas, Koehler, Philipp, Lehrnbecher, Thomas, Kumar, Anil, Prattes, Juergen, Richardson, Malcolm, Revankar, Sanjay, Slavin, Monica A, Stemler, Jannik, Spiess, Birgit, Taj-Aldeen, Saad J, Warris, Adilia, Woo, Patrick C Y, Young, Jo-Anne H, Albus, Kerstin, Arenz, Dorothee, Arsic-Arsenijevic, Valentina, Bouchara, Jean-Philippe, Chinniah, Terrence Rohan, Chowdhary, Anuradha, de Hoog, G Sybren, Dimopoulos, George, Duarte, Rafael F, Hamal, Petr, Meis, Jacques F, Mfinanga, Sayoki, Queiroz-Telles, Flavio, Patterson, Thomas F, Rahav, Galia, Rogers, Thomas R, Rotstein, Coleman, Wahyuningsih, Retno, Seidel, Danila, and Cornely, Oliver A

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results